Cart
sales@molnova.com
WIN 55,212-2 mesylate
CAS No. 131543-23-2
WIN 55,212-2 mesylate ( R)-(+)-WIN 55212;WIN 55212-2 )
Catalog No. M11277 CAS No. 131543-23-2
WIN 55,212-2 mesylate (WIN 55212-2) is a potent cannabinoid receptor agonist with Ki of 62.3 and 3.3 nM for human recombinant CB1 and CB2 receptors, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | 184 | In Stock |
|
| 50MG | 260 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameWIN 55,212-2 mesylate
-
NoteResearch use only, not for human use.
-
Brief DescriptionWIN 55,212-2 mesylate (WIN 55212-2) is a potent cannabinoid receptor agonist with Ki of 62.3 and 3.3 nM for human recombinant CB1 and CB2 receptors, respectively.
-
DescriptionWIN 55,212-2 mesylate (WIN 55212-2) is a potent cannabinoid receptor agonist with Ki of 62.3 and 3.3 nM for human recombinant CB1 and CB2 receptors, respectively; increases extracellular glutamate levels, displaying a bell-shaped concentration-response curve at 0.01-100 nM; increases dialysate glutamate levels the prefrontal cortex from of the awake rats, also demonstrates anticonvulsant effect in vivo pre-treated with 20 mg/kg of pioglitazone.
-
SynonymsR)-(+)-WIN 55212;WIN 55212-2
-
PathwayGPCR/G Protein
-
TargetCannabinoid Receptor
-
RecptorCB1R;CB2R
-
Research AreaNeurological Disease
-
Indication——
Chemical Information
-
CAS Number131543-23-2
-
Formula Weight522.62
-
Molecular FormulaC28H30N2O6S
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 34 mg/mL
-
SMILESO=C(C1=C(C)N2[C@H](CN3CCOCC3)COC4=CC=CC1=C24)C5=C6C=CC=CC6=CC=C5.CS(=O)(O)=O
-
Chemical NameMethanone, [(3R)-2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenyl-, methanesulfonate (1:1)
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Felder CC, et al. Mol Pharmacol. 1995 Sep;48(3):443-50.
2. Griffin G, et al. J Pharmacol Exp Ther. 1998 May;285(2):553-60.
3. D'Ambra TE, et al. J Med Chem. 1992 Jan;35(1):124-35.
4. Martellotta MC, et al. Neuroscience. 1998 Jul;85(2):327-30.
2. Griffin G, et al. J Pharmacol Exp Ther. 1998 May;285(2):553-60.
3. D'Ambra TE, et al. J Med Chem. 1992 Jan;35(1):124-35.
4. Martellotta MC, et al. Neuroscience. 1998 Jul;85(2):327-30.
molnova catalog
related products
-
RVD-Hpα
N-terminally extended form of human hemopressin that acts as a selective CB1 receptor agonist. Increases intracellular Ca2+ levels in cells expressing CB1 receptors in vitro. Also high affinity CB2 positive allosteric modulator (Ki = 50 nM).
-
CB1 antagonist 2
CB1 antagonist 2 is caimabinoid 1 (CB1) antagonist extracted from patent WO2016184310A1, compound 3. Which inhibits CB1 in vivo with an IC50 of 25.5 nM.
-
AM251
AM251 is a potent CB1 receptor antagonist (IC50 = 8 nM, Ki = 7.49 nM) that displays 306-fold selectivity over CB2 receptors; also potent GPR55 agonist (EC50 = 39 nM).
